Aroa BiosurgeryAROAF +35.24%39 EPS without NRI is $0.01 as of Mar. 2026. GuruFocus rates AROAF with a GF Score™ of 39/100 and a GF Value™ of $0.71 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 667 Medical Devices & Instruments companies, Aroa Biosurgery ranks worse than 149924.89% on this metric.
Aroa Biosurgery's earnings per share without non-recurring items for the
six
months ended in Mar. 2026 was $0.01.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Aroa Biosurgery's EPS without NRI or its related term are showing as below:
During the past 7 years, Aroa Biosurgery's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 24.20% per year. The lowest was 22.00% per year. And the median was 23.10% per year.
AROAF's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 8.1 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Aroa Biosurgery's EPS (Diluted) for the
six
months ended in Mar. 2026 was $0.01.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01.
Aroa Biosurgery's EPS (Basic) for the
six
months ended in Mar. 2026 was $0.01.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01.
Aroa Biosurgery (OTCPK:AROAF) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Aroa Biosurgery EPS without NRI Related Terms
Aroa Biosurgery EPS without NRI Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AROAF vs ABT, SYK, MDT: EPS without NRI Comparison
For the Medical Devices subindustry, Aroa Biosurgery's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery (AROAF) has a EPS without NRI of $0.01 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Aroa Biosurgery and its competitors. According to the industry distribution chart, Aroa Biosurgery ranks #999999 out of 667 companies in the Medical Devices & Instruments industry.
Is Aroa Biosurgery's EPS without NRI too high?
Aroa Biosurgery's current EPS without NRI is $0.01. The Medical Devices & Instruments industry median EPS without NRI is 8.10. Aroa Biosurgery's value of $0.01 is 99.9% below this industry median. Based on the distribution chart, Aroa Biosurgery ranks #999999 out of 667 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Aroa Biosurgery has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's EPS without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #999999 out of 667 companies for EPS without NRI. This places Aroa Biosurgery in the lower half of its industry. The industry median EPS without NRI is 8.10. Aroa Biosurgery's value of $0.01 is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.10, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current EPS without NRI of $0.01 is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Aroa Biosurgery and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current EPS without NRI is $0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (AROAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.71, compared to a current price of $0.52 — trading 26.8% below its estimated fair value. The current EPS without NRI is $0.01 and 99.9% below the Medical Devices & Instruments industry median of 8.10. Aroa Biosurgery's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Aroa Biosurgery (AROAF), the current EPS without NRI is $0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (AROAF) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of $0.52 is trading 26.8% below its estimated GF Value™ of $0.71.
GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.
Key valuation signals for AROAF:
EPS without NRI: $0.01
GF Value™: $0.71 vs. price of $0.52 (26.8% below fair value)
Industry Position: 99.9% below the Medical Devices & Instruments median (#999999 of 667)
No single metric tells the full story. See the AROAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
39GF Score
Get the complete analysis for AROAF
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AROAF has been successfully added to your 
